Alvotech vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Alvotech (ALVO)

Q3 202618 Jun – 31 Aug 2026

▲2▼1

Alvotech's FDA Wins and Lotus Deal Offset Heavy Dilution

Dilution from $125M equity raise Alvotech sold new shares to raise about $125 million, which means each existing share now represents a smaller slice of the company. That dilutes current holders and is a direct drag on the stock price, even though the cash funds biosimilar development and launches.
This is the first major event of the period and a clear negative price driver.
$240M total capital raised, but costly debt Alvotech added a $75 million term loan to the $165 million equity raise, giving it $240 million in fresh capital for its pipeline and global expansion. The loan carries a high 12.5% interest rate, so it strengthens the balance sheet but adds real leverage risk that could weigh on future profits.
This is the period's key financing update and explains both the cash cushion and the added risk.
FDA clears Reykjavik plant, unlocking biosimilar approvals The FDA closed its inspection of Alvotech's Iceland factory with a clean 'Voluntary Action Indicated' status, meaning problems were fixed. This removes a regulatory cloud and supports pending U.S. applications for several biosimilars, making future approvals and sales more likely.
This is a new regulatory milestone that directly lifts the stock and de-risks the pipeline.
Lotus deal and AVT80 FDA acceptance expand market reach Alvotech signed a licensing deal with Lotus for two biosimilars worth up to $150 million plus supply revenue, and the FDA accepted its application for AVT80, a subcutaneous Entyvio biosimilar. Both broaden access to oncology, hematology and gut-disease markets, though near-term revenue still depends on approval timing.
These are the period's main growth catalysts, adding new revenue streams and pipeline progress.

July 202618 Jun – 31 Aug 2026

▲2▼1

Alvotech's FDA Wins and Lotus Deal Offset Heavy Dilution

Dilution from $125M equity raise Alvotech sold new shares to raise about $125 million, which means each existing share now represents a smaller slice of the company. That dilutes current holders and is a direct drag on the stock price, even though the cash funds biosimilar development and launches.
This is the first major event of the period and a clear negative price driver.
$240M total capital raised, but costly debt Alvotech added a $75 million term loan to the $165 million equity raise, giving it $240 million in fresh capital for its pipeline and global expansion. The loan carries a high 12.5% interest rate, so it strengthens the balance sheet but adds real leverage risk that could weigh on future profits.
This is the period's key financing update and explains both the cash cushion and the added risk.
FDA clears Reykjavik plant, unlocking biosimilar approvals The FDA closed its inspection of Alvotech's Iceland factory with a clean 'Voluntary Action Indicated' status, meaning problems were fixed. This removes a regulatory cloud and supports pending U.S. applications for several biosimilars, making future approvals and sales more likely.
This is a new regulatory milestone that directly lifts the stock and de-risks the pipeline.
Lotus deal and AVT80 FDA acceptance expand market reach Alvotech signed a licensing deal with Lotus for two biosimilars worth up to $150 million plus supply revenue, and the FDA accepted its application for AVT80, a subcutaneous Entyvio biosimilar. Both broaden access to oncology, hematology and gut-disease markets, though near-term revenue still depends on approval timing.
These are the period's main growth catalysts, adding new revenue streams and pipeline progress.

Latest18 Jun – 31 Aug 2026

▲2▼1

Alvotech's FDA Wins and Lotus Deal Offset Heavy Dilution

Dilution from $125M equity raise Alvotech sold new shares to raise about $125 million, which means each existing share now represents a smaller slice of the company. That dilutes current holders and is a direct drag on the stock price, even though the cash funds biosimilar development and launches.
This is the first major event of the period and a clear negative price driver.
$240M total capital raised, but costly debt Alvotech added a $75 million term loan to the $165 million equity raise, giving it $240 million in fresh capital for its pipeline and global expansion. The loan carries a high 12.5% interest rate, so it strengthens the balance sheet but adds real leverage risk that could weigh on future profits.
This is the period's key financing update and explains both the cash cushion and the added risk.
FDA clears Reykjavik plant, unlocking biosimilar approvals The FDA closed its inspection of Alvotech's Iceland factory with a clean 'Voluntary Action Indicated' status, meaning problems were fixed. This removes a regulatory cloud and supports pending U.S. applications for several biosimilars, making future approvals and sales more likely.
This is a new regulatory milestone that directly lifts the stock and de-risks the pipeline.
Lotus deal and AVT80 FDA acceptance expand market reach Alvotech signed a licensing deal with Lotus for two biosimilars worth up to $150 million plus supply revenue, and the FDA accepted its application for AVT80, a subcutaneous Entyvio biosimilar. Both broaden access to oncology, hematology and gut-disease markets, though near-term revenue still depends on approval timing.
These are the period's main growth catalysts, adding new revenue streams and pipeline progress.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.